Meta Health Limited

As of June 30, 2026, Meta Health Limited carries a market capitalization of 5.28M, placing it among publicly traded companies globally. Its enterprise value stands at 7.32M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Meta Health Limited has 1.32B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.34, and the price-to-book ratio stands at -2.92.

These figures are as of June 30, 2026. The EV/Sales ratio of 10.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.32M versus a market cap of 5.28M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Meta Health Limited maintains a current ratio of 0.41, meaning it holds 0.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -124.88, indicating conservative leverage, while an interest coverage ratio of -3.91 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -26.08, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Meta Health Limited's stock has declined approximately 60.00% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.

Over the twelve months ended June 30, 2026, Meta Health Limited generated 720,000.00 in revenue and converted that into -464,000.00 in net income, yielding earnings per share of 0.00. EBITDA reached -403,000.00, while operating income came in at -434,000.00.

As of June 30, 2026, Meta Health Limited holds 247,000.00 in cash and equivalents against 2.40M in total debt, resulting in a net debt position of 2.06M. Total book value stands at -1.81M, with working capital of -2.16M providing operational flexibility.

Meta Health Limited produced -62,000.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Meta Health Limited posted a gross margin of 92.22, reflecting its pricing power and cost economics. The operating margin of -60.28 and net profit margin of -64.44 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.17: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.12, meaning Meta Health Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Meta Health Limited's most recent stock split took place on January 16, 2025 with a 34:35 split ratio.

As of June 30, 2026, Meta Health Limited has an Altman Z-Score of -29.80, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.